This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

December 2021
Brussels, Venue TBC

Competition Law in the Pharmaceutical Sector

Dissect policy and case law developments. Analyse the latest market trends. Connect with your peers.

Benefit from in-depth insight from our diverse speaker faculty.

Thank you to all those who attended in 2020!


We're currently putting the 2021 programme together - if you'd like to know once it's ready then please register your interest by downloading the 2020 agenda here

Essential updates at the 2020 Competition Law in the Pharma Sector:


COVID-19 & Competition Law
COVID-19 & Competition Law

Analyse the implications of the COVID-19 pandemic on competition law in the pharma sector including new forms of cooperation, supply chain and distribution models, pricing pressures and the role of industry associations in policy changes. 

Mergers in the Pharma Sector
Mergers in the Pharma Sector

Discuss recent developments in mergers including killer acquisitions, the role of innovation, FDI guidelines, and divestments. Join in-house lawyers to hear their best strategies to address practical problems including gun-jumping.

Global Enforcers’ Roundtable
Global Enforcers’ Roundtable

For the first time in this event's history benefit from an analysis of developments beyond Europe during the global enforcers' roundtable. 


Reverse Patent Settlements
Reverse Patent Settlements

Review Paroxetine, Lundbeck and GSK judgements and analyse their practical implications for reverse patent settlements.

Excessive Pricing, Discounts & Rebates
Excessive Pricing, Discounts & Rebates

Review recent high-profile cases including UK’s Pfizer/Flynn and investigations into off-patent medicines, as well as recent developments in discounts and rebates including price caps and pricing considerations during the COVID-19 pandemic.

Biologics and Biosimilars
Biologics and Biosimilars

How is the Commission approaching biologics and biosimilars? Should biosimilars be treated in the same way as generics? What are the practical considerations for products entering markets? Gain in-depth insights into these key questions.

B Vos

Eli Lilly & Co

Of great practical relevance for in-house counsel in the pharmaceutical sector.

Knowledge Partner:

Media Partner